PatientsLikeMe and Shire Pharmaceuticals collaborate to study rare genetic diseases
- Details
- Category: Shire
PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of patient health and disease. Shire, the global leader in rare diseases and other highly specialized conditions, will work with PatientsLikeMe to appropriately engage patients and caregivers at every stage of their journey.
Health risk assessments shed light on early predictors of depression
- Details
- Category: Johnson & Johnson
A new research study supported by Johnson & Johnson Health and Wellness Solutions suggests that health risk assessments (HRAs) can help predict depression in segments of the population who may not be routinely screened in traditional healthcare settings. HRAs are often used by employers and health plans to identify modifiable health risks, such as stress, sleep and quality of life. This new study demonstrates the value of HRAs to identify predictors for depression.
Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global, randomised phase III ALEX study met its primary endpoint and showed that Alecensa® (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
- Details
- Category: Novartis
Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing conditions including regulatory approvals. The financial and other terms of this transaction are not disclosed. ECF843 is a recombinant human lubricin (rh-Lubricin) protein, developed by Lubris LLC, Boston, USA.
First collaborative definition of patient centricity
- Details
- Category: AstraZeneca
AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-developed with patients and caregivers using research led by AstraZeneca and patient community advocates to ensure a deep understanding of patient needs and values. Ten associated patient-centric principles were also identified and published in
Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the phase III ALUR study met its primary endpoint, demonstrating that Alecensa® (alectinib) significantly improved progression-free survival (PFS) in people with anaplastic lymphoma kinase (ALK)-positive advanced (metastatic) non-small cell lung cancer (NSCLC) who had progressed following treatment with one prior line of both platinum-based chemotherapy and crizotinib, compared with chemotherapy.
Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
- Details
- Category: Novo Nordisk
Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories.
More Pharma News ...
- The first overall survival data from the Phase 3 CheckMate -067 clinical trial
- Tagrisso (osimertinib) receives US FDA full approval
- Merck advances R&D strategy through unique development model with Avillion for Anti IL-17 A/F Nanobody
- Daiichi Sankyo announces collaborative research on drugs for neglected tropical diseases
- FDA approves Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis
- Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute announce collaboration to accelerate immuno-oncology research
- Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017